INSIGHTS ON DRUG DEVELOPMENT

DRUG DEVELOPMENT SOLUTIONS

  • STELLARIS STED Microscope

    Get faster to the truth

    Our STED (stimulated emission depletion) technology joins the STELLARIS platform to provide you the fastest way of imaging beyond the diffraction limit. Obtain cutting-edge nanoscopy results in no time with astounding image quality and resolution, while protecting your sample. STED super-resolution allows you to study multiple dynamic events simultaneously, so you can investigate molecular relationships and mechanisms within the cellular context.

    The seamless integration of STED and STELLARIS provides easy access to STED directly from the confocal interface, making it just a few clicks away. Now you can get more insights from your sample, because every detail matters.

  • Uniquely Ergonomic System Microscopes With Intelligent Automation Leica DM3000 LED

    Enhance Laboratory Workflow

    The Leica DM3000 LED microscopes for pathology, cytology, haematology and many other applications feature a motorized nosepiece, condenser head, automated light intensity adjustment, and optional foot pedal. These intuitive microscopes improve workflows significantly. For special diagnostics requirements, the microscope is certified for in-vitro-diagnostics (IVD) like in-vitro-fertilization (IVF).

  • As part of Stevanato Group’s commitment to R&D, our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs. Stevanato Group relies on a multi-disciplinary team of highly skilled professionals, including, scientists, engineers, pharmaceutical chemists and biotechnologists. Their knowledge and experience covers a range of specialized areas including container closure systems and drug-delivery devices.

  • The SpectraMax® Mini Multi-Mode Microplate Reader

    Perform your favorite applications including ELISA, DNA and protein quantitation, cell viability, gene expression with a user-friendly reader.

  • Learn how high‑potency infrastructure, strong impurity control, and scalable payload‑linker capabilities help teams manage risk, maintain purity, and advance toward clinical‑stage ADC development.